Data as of 2026-08-28. Phases: Early Phase 1: 39, Phase 1: 817, Phase 2: 1402, Phase 3: 419, Phase 4: 39.
Lung cancer splits into two clinically distinct histologies. Non-small cell lung cancer (NSCLC) accounts for the large majority of trials and is increasingly segmented by molecular driver — EGFR, KRAS G12C, HER2, ALK, ROS1, BRAF, and RET — each with its own targeted-therapy program. Small cell lung cancer (SCLC) is a separate, faster-growing histology with a distinct trial set. A useful lung-cancer competitive picture has to track both the histology split and the molecular-subtype races at once.
Molecular-driver subtypes are subsets of NSCLC and overlap each other, so the rows below do not sum to the total above — each links to a dedicated biomarker landscape. KRAS G12C spans lung, colorectal, and pancreatic cancer; its page covers all indications.
By histology
| Subtype | Active | Recruiting | Phase 3 |
|---|---|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | 1684 | 894 | 241 |
| Small Cell Lung Cancer (SCLC) | 362 | 196 | 47 |
By molecular driver (within NSCLC)
| Subtype | Active | Recruiting | Phase 3 |
|---|---|---|---|
| EGFR-mutant | 400 | 193 | 66 |
| KRAS G12C | 72 | 32 | 16 |
| HER2-mutant | 87 | 50 | 8 |
| ALK-positive | 79 | 29 | 10 |
| ROS1 fusion | 38 | 19 | 5 |
| BRAF V600E | 10 | 4 | 1 |
| RET fusion | 8 | 2 | 2 |
Track every new lung cancer trial automatically
ClinicalTrials.gov updates daily. Our pipeline monitors it for you and delivers a clean digest every morning.
Get free alerts, no credit cardLargest industry-sponsored lung cancer trial portfolios by active study count:
| Sponsor | Active trials |
|---|---|
| AstraZeneca | 99 |
| Merck (MSD) | 37 |
| Pfizer | 32 |
| Sichuan Baili Pharmaceutical Co., Ltd. | 29 |
| Bristol-Myers Squibb | 27 |
Our pipeline pulls from ClinicalTrials.gov every day. For a lung cancer watchlist or saved search, alerts cover:
- New study registrations and status changes (for example opened to recruiting, completed)
- Protocol changes: enrollment, endpoints, phase, and completion-date movements
- New sponsor entrants into a subtype
- Phase filters (Phase 1 for novel mechanisms, Phase 3 for registration programs)
- Sponsor-type filters (large pharma vs. emerging biotech vs. academic)
Ready to automate your lung cancer trial monitoring?
Free plan, no credit card required. Set up your profile in 2 minutes.
Start freeFrequently asked questions
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search with email alerts, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.
Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches with email alerts, track up to 25 individual trials, full Trials at Risk list and landscape reports.
Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.
Data as of 2026-08-28, from ClinicalTrials.gov. View the full pipeline on the dashboard.